Target Lesion Failure and Stent Thrombosis Rates Low With SYNERGY
Diabetes, acute MI, and history of CABG were among the predictors of incidence and early time to TLF.
WASHINGTON, DC — Use of the coronary stent SYNERGY (Boston Scientific Corporation) was associated with low rates of target lesion revascularization (TLR) and stent thrombosis, according to data presented at the 66th Annual Scientific Session & Expo of the American College of Cardiology.
Unlike other drug-eluting stents, SYNERGY stents are coated with a bioabsorbable abluminal polymer that dissolves after 4 months.
Researchers from the National University Heart Centre in Singapore conducted a prospective, single-center postmarketing registry of 765 consecutive patients (1279 stents; mean age, 60.7 years; 83.4% men) undergoing percutaneous coronary intervention with the SYNERGY stent. The primary outcome was the incidence of target lesion failure (TLF) at 1 year, defined as the combination of cardiac death, target vessel myocardial infarction (MI), or clinically driven TLR.
Of the multiethnic Asian patient population, 38.7% had diabetes and 50.3% had acute MI. Many of the treated lesions were considered complex (American College of Cardiology/American Heart Association type B2/C: 72.7%). At 1 year, the TLF rate was 5.8%, and rates of cardiac mortality, target vessel MI, and TLR were 4.2%, 1.0%, and 1.3%, respectively.
Female sex, Malay ethnicity, diabetes, acute MI, and history of coronary artery bypass surgery were predictors of incidence and early time to TLF. In addition, moderate/severe calcification and ostial location of lesions predicted early time to TLF. Finally, definite/probable stent thrombosis was 0.5% at 1 year.
Ping Yun Loh J, Anathakrishna R, Kristanto W, et al. Incidence and predictors of target lesion failure in a multi-ethnic Asian population receiving the SYNERGY coronary stent: a prospective all-comers registry. Abstract 1286-179. Presented at: the 66th Annual Scientific Session & Expo of the American College of Cardiology. March 17-19, 2017; Washington, DC.